The underdiagnosed kidney burden of Fabry disease in females

Abstract

Aim: Progressive kidney deterioration can occur in females with Fabry disease. Despite this, many females go undiagnosed or are labeled “carriers”. Our study aimed to review biopsy findings of adult female Fabry patients with creatinine values within the “normal reference ranges” and minimal proteinuria.

Methods: This study was a single-center retrospective analysis of female patients presenting to the University of Alabama at Birmingham. Kidney biopsies and clinical characteristics were reviewed. Kidney biopsies were scored using the Fogo scoring system.

Results: All of the 13 participants had classic mutations (11 nonsense, 2 missense). The mean age was 31.7 years. The median serum creatinine was 0.7 mg/dL (0.5-1.2), and estimated glomerular filtration rate (eGFR) values calculated using the chronic kidney disease epidemiology collaboration (CKD-EPI) equation ranged from 56 to 130 ml/min/1.73m². The serologic biomarkers were not elevated in any of the patients - plasma globotriaosylsphingosine (Lyso GL-3) was < 5.1 ng/mL and globotriaosylceramide (GL-3) was < 3 µg/mL. The average score for the biopsies per the International Study Group of Fabry Nephropathy (ISGFN) was 2.43. Thirty-eight percent of patients had greater than 50% foot process effacement despite normal creatinine and minimal proteinuria.

Conclusion: Females with Fabry disease, despite having normal reference range creatinine, minimal proteinuria, and low plasma Lyso GL-3, had significant histologic evidence of the disease. When possible, histologic assessment should be performed in females to assess tissue involvement. Longitudinal follow-up is needed to determine if histologic findings on presentation predict long-term outcomes.

Keywords

Fabry disease / alpha-galactosidase A / glycosphingolipidosis / kidney biopsy / podocytes / proteinuria.

References

[1] Germain DP.Fabry disease.Orphanet J Rare Dis2010;5:30 PMCID:PMC3009617

[2] Lukas J,Markoff A.Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in Fabry disease.PLoS Genet2013;9:e1003632 PMCID:PMC3731228

[3] Eng CM,Wilcox WR.Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the fabry registry.J Inherit Metab Dis2007;30:184-92

[4] Galanos J,Grigg L,Crawford A.Clinical features of Fabry's disease in Australian patients.Intern Med J2002;32:575-84

[5] Gupta S,Kotsopoulos S.The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women.Medicine2005;84:261-8

[6] Orteu CH,Lidove O.FOS InvestigatorsFabry disease and the skin: data from FOS, the Fabry outcome survey.Br J Dermatol2007;157:331-7

[7] Echevarria L,Toussaint A.X-chromosome inactivation in female patients with Fabry disease.Clin Genet2016;89:44-54

[8] Merscher S.Podocyte pathology and nephropathy - sphingolipids in glomerular diseases.Front Endocrinol2014;5:127 PMCID:PMC4115628

[9] Baxmann AC,Marques NC.Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C.Clin J Am Soc Nephrol2008;3:348-54 PMCID:PMC2390952

[10] Kilbride HS,Eaglestone G.Accuracy of the MDRD (modification of diet in renal disease) study and CKD-EPI (CKD epidemiology collaboration) equations for estimation of GFR in the elderly.Am J Kidney Dis2013;61:57-66

[11] Sakuraba H,Tsukimura T.Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy.Clin Exp Nephrol2018;22:843-9

[12] Young E,Morris P.Is globotriaosylceramide a useful biomarker in Fabry disease?.Acta Paediatr Suppl2005;94:51-4; discussion 37

[13] Fogo AB,Svarstad E.all members of the International Study Group of Fabry Nephropathy (ISGFN)Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN).Nephrol Dial Transplant2010;25:2168-77 PMCID:PMC2902894

[14] Valbuena C,Bustorff M.Kidney biopsy findings in heterozygous Fabry disease females with early nephropathy.Virchows Arch2008;453:329-38

[15] Fischer EG,Lager DJ.Fabry disease: a morphologic study of 11 cases.Mod Pathol2006;19:1295-301

[16] Germain DP,Barriales-Villa R.An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease.Mol Genet Metab2022;137:49-61

[17] van der Tol L,Ortiz A.Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosis.Mol Genet Metab2015;114:242-7

[18] Najafian B,Sokolovskiy A.A novel unbiased method reveals progressive podocyte globotriaosylceramide accumulation and loss with age in females with Fabry disease.Kidney Int2022;102:173-82 PMCID:PMC9233139

[19] Tøndel C,Larsen KK.Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria.Nephron2015;129:16-21

[20] Rusu EE,Ciobotaru LM.The impact of kidney biopsy for Fabry nephropathy evaluation on patients' management and long-term outcomes: experience of a single center.Biomedicines2022;10:1520

[21] Tøndel C,Hirth A.Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria.Am J Kidney Dis2008;51:767-76

[22] Waldek S,Banikazemi M,Lee P.Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry registry.Genet Med2009;11:790-6

[23] Burlina A,Hughes D.An expert consensus on the recommendations for the use of biomarkers in Fabry disease.Mol Genet Metab2023;139:107585

[24] Hsu TR,Chu TH.Correlations between endomyocardial biopsies and cardiac manifestations in taiwanese patients with the Chinese hotspot IVS4+919G>A mutation: data from the Fabry outcome survey.Int J Mol Sci2017;18:119

[25] Umer M.Treatment of Fabry disease: established and emerging therapies.Pharmaceuticals2023;16:320 PMCID:PMC9967779

[26] Germain DP.Pegunigalsidase alfa: a novel, pegylated recombinant alpha-galactosidase enzyme for the treatment of Fabry disease.Front Genet2024;15:1395287 PMCID:PMC11045972